In Lilly vs Novo obesity drug battle, Trump price talks grab focus

Core Viewpoint - The focus is shifting towards high-stakes price negotiations between obesity drug manufacturers Eli Lilly and Novo Nordisk and U.S. President Donald Trump as they prepare to release their third-quarter results [1] Company Insights - Eli Lilly and Novo Nordisk are major players in the obesity drug market, indicating their significant role in the healthcare industry [1] - The upcoming third-quarter results are highly anticipated by investors, reflecting the importance of these companies in the current market landscape [1] Industry Context - The ongoing price talks with the U.S. government highlight the increasing scrutiny and regulatory pressures faced by pharmaceutical companies, particularly in the obesity treatment sector [1] - The outcome of these negotiations could have substantial implications for pricing strategies and market dynamics within the obesity drug industry [1]